Rorabaugh Boyd R, Chakravarti Bandana, Mabe Nathaniel W, Seeley Sarah L, Bui Albert D, Yang Jianqi, Watts Stephanie W, Neubig Richard R, Fisher Rory A
Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, Ohio (B.R.R., N.W.M., S.L.S., A.D.B.); Department of Pharmacology, Carver College of Medicine, University of Iowa, Iowa City, Iowa (B.C., J.Y., R.A.F.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (S.W.W., R.R.N.)
Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, Ohio (B.R.R., N.W.M., S.L.S., A.D.B.); Department of Pharmacology, Carver College of Medicine, University of Iowa, Iowa City, Iowa (B.C., J.Y., R.A.F.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (S.W.W., R.R.N.).
J Pharmacol Exp Ther. 2017 Mar;360(3):409-416. doi: 10.1124/jpet.116.238345. Epub 2016 Dec 29.
Gαi-coupled receptors play important roles in protecting the heart from ischemic injury. Regulator of G protein signaling (RGS) proteins suppress Gαi signaling by accelerating the GTPase activity of Gαi subunits. However, the roles of individual RGS proteins in modulating ischemic injury are unknown. In this study, we investigated the effect of RGS6 deletion on myocardial sensitivity to ischemic injury. Hearts from RGS6 knockout (RGS6) and RGS6 wild-type (RGS6) mice were subjected to 30 minutes of ischemia and 2 hours of reperfusion on a Langendorff heart apparatus. Infarcts in RGS6 hearts were significantly larger than infarcts in RGS6 hearts. RGS6 hearts also exhibited increased phosphorylation of β-adrenergic receptors and G protein-coupled receptor kinase 2 (GRK2). Mitochondrial GRK2 as well as caspase-3 cleavage were increased significantly in RGS6 hearts compared with RGS6 hearts after ischemia. Chronic propranolol treatment of mice prevented the observed increases in ischemic injury and the GRK2 phosphorylation observed in RGS6 hearts. Our findings suggest that loss of RGS6 predisposes the ventricle to prodeath signaling through a βAR-GRK2-dependent signaling mechanism, and they provide evidence for a protective role of RGS6 in the ischemic heart. Individuals expressing genetic polymorphisms that suppress the activity of RGS6 may be at increased risk of cardiac ischemic injury. Furthermore, the development of agents that increase RGS6 expression or activity might provide a novel strategy for the treatment of ischemic heart disease.
Gαi偶联受体在保护心脏免受缺血性损伤中发挥重要作用。G蛋白信号调节剂(RGS)蛋白通过加速Gαi亚基的GTP酶活性来抑制Gαi信号传导。然而,单个RGS蛋白在调节缺血性损伤中的作用尚不清楚。在本研究中,我们研究了RGS6缺失对心肌缺血性损伤敏感性的影响。将RGS6基因敲除(RGS6-/-)和RGS6野生型(RGS6+/+)小鼠的心脏在Langendorff心脏装置上进行30分钟的缺血和2小时的再灌注。RGS6-/-心脏的梗死面积明显大于RGS6+/+心脏的梗死面积。RGS6-/-心脏还表现出β-肾上腺素能受体和G蛋白偶联受体激酶2(GRK2)磷酸化增加。与缺血后的RGS6+/+心脏相比,RGS6-/-心脏中的线粒体GRK2以及半胱天冬酶-3的裂解显著增加。对小鼠进行慢性普萘洛尔治疗可防止观察到的缺血性损伤增加以及RGS6-/-心脏中观察到的GRK2磷酸化。我们的研究结果表明,RGS6的缺失通过βAR-GRK2依赖性信号传导机制使心室易发生促死亡信号传导,并为RGS6在缺血心脏中的保护作用提供了证据。表达抑制RGS6活性的基因多态性的个体可能增加心脏缺血性损伤的风险。此外,开发增加RGS6表达或活性的药物可能为治疗缺血性心脏病提供一种新策略。